(Q36625908)

15 August 2017

Cost of managing women presenting with stage IV breast cancer in the United Kingdom (English)

1 reference

15 August 2017

E Remák

1

1 reference

15 August 2017

L Brazil

series ordinal

2

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2004

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

91

1 reference

15 August 2017

1

1 reference

15 August 2017

77-83

1 reference

The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364734

Advanced breast cancer: use of resources and cost implications

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364734

Stage IV breast cancer: clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis. The GOCS (Grupo Oncológico Cooperativo del Sur) experience

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364734

Bone-only versus visceral-only metastatic pattern in breast cancer: analysis of 150 patients. A GOCS study. Grupo Oncológico Cooperativo del Sur.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364734

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364734

Costs of breast cancer treatment in the United Kingdom

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601890

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

21 January 2018

1 reference

12 December 2020

The costs of treating breast cancer in the United Kingdom: implications for screening

1 reference

12 December 2020

Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy

1 reference

12 December 2020

Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients

1 reference

12 December 2020

Cost-of-illness studies: a major headache?

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Surgical treatment of bone metastases in patients with breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601890

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

15188011

1 reference